Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Cary Hickman

Internal Medicine Charleston, SC Medical Doctor

NPI 1134171440 CMS profile 323478

615 Wesley Drive, Suite 200, Charleston, SC 29407

Open in the dashboard

General payments

$3,042

185 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Cary Hickman of Charleston, SC is reported in the CMS Open Payments database as having received $3,042 across 185 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 84th percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $518 25
2024 General $485 27
2023 General $547 31
2022 General $133 8
2021 General $130 8
2020 General $175 12
2019 General $1,054 74

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Cary Hickman
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Cary Hickman were reported at $518. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Cary Hickman Internal Medicine median Middle half National median
2019 $1,054 $159 $48–$570 $163
2020 $175 $119 $33–$402 $114
2021 $130 $135 $37–$521 $132
2022 $133 $141 $42–$496 $149
2023 $547 $149 $45–$519 $160
2024 $485 $154 $47–$537 $164
2025 $518 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Pfizer Inc. $538 36 payments
  2. GlaxoSmithKline, LLC. $281 17 payments
  3. Lilly USA, LLC $238 13 payments
  4. Novo Nordisk Inc $191 12 payments
  5. Amgen Inc. $181 10 payments
  6. E.R. Squibb & Sons, L.L.C. $167 12 payments
  7. Salix Pharmaceuticals, a division of Bausch Health US, LLC $133 7 payments
  8. Boehringer Ingelheim Pharmaceuticals, Inc. $116 7 payments
  9. Abbott Laboratories $97 4 payments
  10. Janssen Pharmaceuticals, Inc $91 6 payments
  11. Other $1,007 61 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $3,042 185 payments
Products named General payments · program years 2019–2025
  1. ELIQUIS Cardiovascular;Metabolic Disease $241 15 payments
  2. ELIQUIS Cardiovascular $167 12 payments
  3. NURTEC ODT $151 9 payments
  4. XIFAXAN $133 7 payments
  5. MOUNJARO $125 7 payments
  6. TRELEGY ELLIPTA $123 7 payments
  7. Ozempic $120 8 payments
  8. Repatha $117 6 payments
  9. JARDIANCE $113 6 payments
  10. RYBELSUS $109 7 payments
  11. Other $2,714 171 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 100 drugs

Part D claims

4,468

Median for Internal Medicine: 777

Drug cost

$408,400

Median for Internal Medicine: $73,373

Branded share of claims

18.1%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 48 $65,895
Januvia Sitagliptin Phosphate Brand 60 $58,308
Eliquis Apixaban Brand 59 $51,629
Jardiance Empagliflozin Brand 36 $42,972
Trulicity Dulaglutide Brand 22 $32,486
Xarelto Rivaroxaban Brand 35 $31,752
Rybelsus Semaglutide Brand 13 $18,857
Myrbetriq Mirabegron Brand 27 $18,521
Breo Ellipta Fluticasone/Vilanterol Brand 25 $14,876
Testosterone Generic 39 $7,478

The 10 drugs with the highest cost, of 100 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 43 billing codes

Paid by Medicare

$305,574

Of which drugs: $82,400

Medicare patients

631

Average age 77

Services billed

5,695

324 women, 307 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 49%
Diabetes 29%
Ischemic heart disease 26%
Depression 24%
Chronic kidney disease 21%
Atrial fibrillation 20%
Cancer 20%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Pcv20 vaccine im 90677 Office 138 138 $39,363
Injection, denosumab, 1 mg J0897 Office 20 1,740 $34,972
Vaccine for influenza for injection into muscle 90662 Office 97 97 $7,877

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 20 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Wegovy
  • Novo Nordisk Inc $39
$39 — —
VRAYLAR
  • AbbVie, Inc. $34
$34 — —
ELIQUIS
  • E.R. Squibb & Sons, L.L.C. $16
  • PFIZER INC. $13
$30 59 —
NURTEC ODT
  • PFIZER INC. $28
$28 — —
MOUNJARO
  • Lilly USA, LLC $23
$23 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 20 in the dashboard with a free account

Records

185 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in South Carolina

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record